Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Aug 31:10:69.
doi: 10.1186/1477-7827-10-69.

Outpatient management of severe early OHSS by administration of GnRH antagonist in the luteal phase: an observational cohort study

Affiliations

Outpatient management of severe early OHSS by administration of GnRH antagonist in the luteal phase: an observational cohort study

George T Lainas et al. Reprod Biol Endocrinol. .

Abstract

Background: Management of established severe OHSS requires prolonged hospitalization, occasionally in intensive care units, accompanied by multiple ascites punctures, correction of intravascular fluid volume and electrolyte imbalance. The aim of the present study was to evaluate whether it is feasible to manage women with severe OHSS as outpatients by treating them with GnRH antagonists in the luteal phase.

Methods: This is a single-centre, prospective, observational, cohort study. Forty patients diagnosed with severe OHSS, five days post oocyte retrieval, were managed as outpatients after administration of GnRH antagonist (0.25 mg) daily from days 5 to 8 post oocyte retrieval, combined with cryopreservation of all embryos. The primary outcome measure was the proportion of patients with severe OHSS, in whom outpatient management was not feasible.

Results: 11.3% (95% CI 8.3%-15.0%) of patients (40/353) developed severe early OHSS. None of the 40 patients required hospitalization following luteal antagonist administration and embryo cryopreservation. Ovarian volume, ascites, hematocrit, WBC, serum oestradiol and progesterone decreased significantly (P < 0.001) by the end of the monitoring period, indicating rapid resolution of severe OHSS.

Conclusions: The current study suggests, for the first time, that successful outpatient management of severe OHSS with antagonist treatment in the luteal phase is feasible and is associated with rapid regression of the syndrome, challenging the dogma of inpatient management. The proposed management is a flexible approach that minimizes unnecessary embryo transfer cancellations in the majority (88.7%) of high risk for OHSS patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart describing the management approach for patients at high risk for developing OHSS. 10 patients did not develop severe OHSS and had embryo transfer cancellation due to the following reasons: failed fertilization n = 1, oocyte cryopreservation n = 2, no blastocyst formation n = 2, embryo cryopreservation due to Rokitansky syndrome n = 1, due to poor endometrium n = 1, absence of sperm on day of oocyte retrieval and use of donor sperm n = 3. Four patients with positive hCG following ET developed pregnancy-induced late OHSS and were admitted to the hospital (1.1%, 95% CI: 0.5 to 3.3).
Figure 2
Figure 2
Concentrations of (a) oestradiol (b) progesterone, (c) left and (d) right ovarian volume, (e) hematocrit, and (f) white blood cells during the monitoring period. Asterisks depict statistically significant difference compared to day 5 (*P < 0.001). Oocyte retrieval was performed on day 0. GnRH antagonist was administered from day 5 until and including day 8 post oocyte retrieval, as indicated by arrows.
Figure 3
Figure 3
Distribution of ascites levels during the monitoring period. *At the end of the monitoring period, on day 11, “moderate-marked ascites” included 14 women (35%), of which 11 (27.5%) had moderate ascites, and only 3 (7.5%) had marked ascites. No women (0%) had “massive-tense” ascites, while the majority of women (65%) had no or low levels of ascites on day 11 of monitoring (chi-square p < 0.01).

Similar articles

Cited by

References

    1. Lyons CA, Wheeler CA, Frishman GN, Hackett RJ, Seifer DB, Haning RV. Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors. Hum Reprod. 1994;9(5):792–799. - PubMed
    1. Mathur RS, Akande AV, Keay SD, Hunt LP, Jenkins JM. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril. 2000;73(5):901–907. doi: 10.1016/S0015-0282(00)00492-1. - DOI - PubMed
    1. Aboulghar MA, Mansour RT. Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures. Hum Reprod Update. 2003;9(3):275–289. doi: 10.1093/humupd/dmg018. - DOI - PubMed
    1. Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril. 1992;58(2):249–261. - PubMed
    1. Aboulghar MA, Mansour RT, Serour GI, Sattar MA, Amin YM, Elattar I. Management of severe ovarian hyperstimulation syndrome by ascitic fluid aspiration and intensive intravenous fluid therapy. Obstet Gynecol. 1993;81(1):108–111. - PubMed

MeSH terms